| Kaitlyn E Buxman, PA | |
|
1001 Belmont Ave, Youngstown, OH 44504-1003 | |
| (330) 747-1106 | |
| (330) 747-0491 |
| Full Name | Kaitlyn E Buxman |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 7 Years |
| Location | 1001 Belmont Ave, Youngstown, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497274054 | NPI | - | NPPES |
| 0250349 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 50.005197RX (Ohio) | Secondary |
| 363A00000X | Physician Assistant | 50.005197RX (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth Youngstown Hospital | Youngstown, OH | Hospital |
| Hmhp St Elizabeth Boardman Health Center | Boardman, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health Physicians Youngstown Specialty Care Llc | 3476950296 | 389 |
News Archive
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Authorities in China "have begun a national campaign to crack down on procedures used to determine a fetus' sex for anything other than medical purposes and abortions performed because a fetus is of a certain sex" in an effort to curb the country's growing gender ratio imbalance, China Daily reports.
Researchers from the Bellvitge Biomedical Research Institute in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline.
In an effort to better understand and develop prevention strategies for drug-induced liver injury, physician-scientists from the Icahn School of Medicine at Mount Sinai have joined the Drug-Induced Liver Injury Network, a National Institutes of Health-funded consortium of only six academic medical centers in the United States.
Dr. Kimberly Reynolds, Assistant Professor in the Cecil H. and Ida Green Comprehensive Center for Molecular, Computational, and Systems Biology and in the Department of Biophysics at UT Southwestern Medical Center, has been named one of 14 Moore Investigators in Data-Driven Discovery.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kaitlyn E Buxman, PA 1001 Belmont Ave, Youngstown, OH 44504-1003 Ph: (330) 747-1106 | Kaitlyn E Buxman, PA 1001 Belmont Ave, Youngstown, OH 44504-1003 Ph: (330) 747-1106 |
News Archive
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Authorities in China "have begun a national campaign to crack down on procedures used to determine a fetus' sex for anything other than medical purposes and abortions performed because a fetus is of a certain sex" in an effort to curb the country's growing gender ratio imbalance, China Daily reports.
Researchers from the Bellvitge Biomedical Research Institute in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline.
In an effort to better understand and develop prevention strategies for drug-induced liver injury, physician-scientists from the Icahn School of Medicine at Mount Sinai have joined the Drug-Induced Liver Injury Network, a National Institutes of Health-funded consortium of only six academic medical centers in the United States.
Dr. Kimberly Reynolds, Assistant Professor in the Cecil H. and Ida Green Comprehensive Center for Molecular, Computational, and Systems Biology and in the Department of Biophysics at UT Southwestern Medical Center, has been named one of 14 Moore Investigators in Data-Driven Discovery.
› Verified 2 days ago